Vera Therapeutics

VERA · NASDAQ

$30.06+$1.14 (+3.94%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $28.92

VERA analyst rating

BuyConsensus of 10 analysts over the last 12 months. 80% rate it a buy.

Strong buy0
Buy8
Hold2
Underperform0
Sell0

12-month price target · 16 analysts

Average $78.62 (+161.5% upside)

Low: $34.34
Now: $30.06
High: $105.00

Upgrades and downgrades

The latest rating actions, newest first

VERA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Leerink Partners	Oct 12, 2026	Initiates	Market Perform	$34.00	0%
JP Morgan	Sep 8, 2026	Maintains	Overweight	$76.00 → $83.00	48%
Wedbush	Aug 17, 2026	Maintains	Neutral	$34.00	40%
HC Wainwright & Co.	Aug 12, 2026	Maintains	Buy	$125.00 → $90.00	47%
Wedbush	Aug 11, 2026	Maintains	Neutral	$43.00 → $34.00	40%
TD Cowen	Jul 8, 2026	Maintains	Buy	$73.00 → $78.00	42%
Guggenheim	Jul 8, 2026	Maintains	Buy	$56.00 → $76.00	66%
Wedbush	Jul 8, 2026	Maintains	Neutral	$35.00 → $43.00	40%
HC Wainwright & Co.	Jul 8, 2026	Maintains	Buy	$110.00 → $125.00	47%
B of A Securities	Jul 7, 2026	Maintains	Buy	$65.00 → $70.00	0%

The case for and against

Updated Oct 16, 2026

Bull case

Vera Therapeutics is favored because Trutakna achieved FDA accelerated approval on July 7, becoming the first approved agent targeting both BAFF and APRIL in IgAN, which materially de-risks the platform and gives the company a commercial entry point. The outlook is further strengthened by management’s expectation for the ORIGIN 3 eGFR readout in 3Q26 and an sBLA filing in 4Q26, a timeline that could support potential full approval in 2027 and improve formulary access and adoption. Commercial comparables also look encouraging, as Otsuka’s Voyxact has shown meaningful eGFR gains and early launch traction, while Vera’s 2Q26 update suggests participation in a growing IgAN market with additional upside from Filspari’s 2,012 PSFs in 2Q26.

Bear case

Vera Therapeutics is viewed negatively because its lead asset, atacicept, faces a difficult commercialization path despite encouraging proteinuria and eGFR signals, since FDA materials stress that the interim ORIGIN3 kidney-function data are based on a small sample and carry “considerable uncertainty” about effect size. Competitive pressure is also intensifying after Voyxact’s strong VISIONARY results on August 3, including a +4.5 mL/min/1.73m² annualized eGFR slope advantage at 24 months and monthly dosing that may be more attractive than atacicept’s weekly administration, forcing a lower assumed peak penetration rate to 15% from 20%. Financially, Vera reported no revenue in 2Q26, a $1.52 per-share net loss, and about $499M of cash and investments, but it is still likely to need additional funding while regulatory risk and commercial execution remain unresolved.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.